PAR Investor Meeting - Questions from HC, page-122

There is significant amount of recent research highlighting the hurdles for achieving DMOAD. The upshot is the FDA want to work with all parties to achieve robust endpoints.

PAR_008 continues to hold significant weight but I suspect no longer critical to concluding a global deal. Such a deal would naturally recognise the long term labelling upside of DMOAD but won't monetise it upfront. As such resetting expectations of initial deal metrics. Good luck to all as I expect 2022 will see PAR mature with its public messaging,